NASDAQ:TLSI TriSalus Life Sciences (TLSI) Stock Price, News & Analysis $3.39 +0.12 (+3.79%) As of 03:21 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About TriSalus Life Sciences Stock (NASDAQ:TLSI) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get TriSalus Life Sciences alerts:Sign Up Key Stats Today's Range$3.15▼$3.4050-Day Range$2.52▼$4.6552-Week Range$2.20▼$7.95Volume192,161 shsAverage Volume283,995 shsMarket Capitalization$208.46 millionP/E RatioN/ADividend YieldN/APrice Target$7.50Consensus RatingHold Company Overview TriSalus Life Sciences, Inc. is a clinical-stage biotechnology company focused on the development and commercialization of non-invasive drug–device combination therapies for oncology applications. Leveraging proprietary electroporation and ultrasound platforms, the company aims to enhance the localized delivery and efficacy of established chemotherapeutic agents while reducing systemic toxicity. Its lead programs target hard-to-treat head and neck cancers, where improved tumor control and patient tolerability remain significant unmet needs. The company’s pipeline comprises investigational product candidates in early and mid-stage clinical trials, including studies that combine its electrochemotherapy platform with radiation therapy and immuno-oncology agents. TriSalus collaborates with academic medical centers and cancer research institutions across the United States to advance its candidates through regulatory and clinical milestones. By integrating novel delivery technologies with proven oncology drugs, TriSalus seeks to optimize therapeutic outcomes in both recurrent and metastatic disease settings. Headquartered in Houston, Texas, TriSalus operates research and development facilities in strategic North American life-science hubs. Its leadership team brings together seasoned professionals with backgrounds in pharmaceutical development, medical devices, and oncology therapeutics. As the company progresses through clinical validation, it plans to expand its technology platform into additional solid tumor indications, aiming to provide safer, more effective treatment options for cancer patients worldwide.AI Generated. May Contain Errors. Read More TriSalus Life Sciences Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks75th Percentile Overall ScoreTLSI MarketRank™: TriSalus Life Sciences scored higher than 75% of companies evaluated by MarketBeat, and ranked 196th out of 871 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.7 / 5Analyst RatingHold Consensus RatingTriSalus Life Sciences has received a consensus rating of Hold. The company's average rating score is 2.25, and is based on no strong buy ratings, 2 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialTriSalus Life Sciences has a consensus price target of $7.50, representing about 124.3% upside from its current price of $3.34.Amount of Analyst CoverageTriSalus Life Sciences has only been the subject of 3 research reports in the past 90 days.Read more about TriSalus Life Sciences' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for TriSalus Life Sciences are expected to grow in the coming year, from ($0.45) to ($0.25) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of TriSalus Life Sciences is -2.38, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of TriSalus Life Sciences is -2.38, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioTriSalus Life Sciences has a P/B Ratio of 15.92. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about TriSalus Life Sciences' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted3.28% of the float of TriSalus Life Sciences has been sold short.Short Interest Ratio / Days to CoverTriSalus Life Sciences has a short interest ratio ("days to cover") of 1.65, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in TriSalus Life Sciences has recently increased by 16.84%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldTriSalus Life Sciences does not currently pay a dividend.Dividend GrowthTriSalus Life Sciences does not have a long track record of dividend growth. News and Social Media2.3 / 5News SentimentN/A News SentimentTriSalus Life Sciences has a news sentiment score of 0.63. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.80 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for TriSalus Life Sciences this week, compared to 2 articles on an average week.Search Interest4 people have searched for TLSI on MarketBeat in the last 30 days. Company Ownership4.2 / 5Insider TradingAcquiring Shares Cluster Insider Buying4 insiders have purchased shares of TriSalus Life Sciences in the last three months. Multiple insiders buying is a strong bullish signal.Net Insider BuyingOver the last three months, insiders have purchased a net $1,684,327.00 in company stock, which represents 0.8201% of the company's market cap.Insider Buying vs. Insider SellingIn the past three months, TriSalus Life Sciences insiders have bought 1,405.37% more of their company's stock than they have sold. Specifically, they have bought $1,804,176.00 in company stock and sold $119,849.00 in company stock.Percentage Held by Insiders16.30% of the stock of TriSalus Life Sciences is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions2.58% of the stock of TriSalus Life Sciences is held by institutions.Read more about TriSalus Life Sciences' insider trading history. Receive TLSI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for TriSalus Life Sciences and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. TLSI Stock News HeadlinesTLSI (TLSI) Securities Fraud Investigation - Levi & KorsinskyMay 22, 2026 | prnewswire.comSecurities Fraud Investigation Into TriSalus Life Sciences Inc. (TLSI) Announced - Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading ...May 20, 2026 | tmcnet.comTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no debate, no vote, one executive order. Gold tripled within three years and climbed 20x over the following decade. Trump holds that same executive authority today, and his advisors are openly saying a reversal is on the table. There are two ways this plays out - both move gold in the same direction. A free briefing breaks down exactly what Nixon did, why Trump is positioned to act, and how to move your 401k into gold before any announcement - tax free.May 29 at 1:00 AM | Reagan Gold Group (Ad)Securities Fraud Investigation Into TriSalus Life Sciences Inc. (TLSI) Announced – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law FirmMay 20, 2026 | businesswire.comTriSalus Life Sciences Inc. (TLSI) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud InvestigationMay 20, 2026 | businesswire.comSecurities Fraud Investigation Into TriSalus Life Sciences Inc. (TLSI) Announced - Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. CruzMay 19, 2026 | tmcnet.comTLSI Investor Alert: Levi & Korsinsky Investigates TLSI (TLSI) for Potential Securities FraudMay 19, 2026 | businesswire.comTriSalus Life Sciences (NASDAQ:TLSI) Director Purchases $24,600.00 in StockMay 19, 2026 | insidertrades.comSee More Headlines TLSI Stock Analysis - Frequently Asked Questions How have TLSI shares performed this year? TriSalus Life Sciences' stock was trading at $6.98 at the beginning of 2026. Since then, TLSI shares have decreased by 52.1% and is now trading at $3.3440. How were TriSalus Life Sciences' earnings last quarter? TriSalus Life Sciences, Inc. (NASDAQ:TLSI) issued its quarterly earnings data on Thursday, March, 5th. The company reported ($0.12) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.13) by $0.01. The business earned $13.21 million during the quarter, compared to analysts' expectations of $13.20 million. Read the conference call transcript. Who are TriSalus Life Sciences' major shareholders? Top institutional shareholders of TriSalus Life Sciences include First Light Asset Management LLC (8.26%), Wasatch Advisors LP (2.35%), Empire Financial Management Company LLC (0.49%) and Perkins Capital Management Inc. (0.38%). Insiders that own company stock include Equity Ab Frankenius, Michael P Stansky, Mary T Szela, George Kelly Martin, Sean Murphy, Bryan F Cox, Mats Wahlstrom, Richard Marshak, Jodi Devlin, Gary B Gordon and James Emmett Young. View institutional ownership trends. How do I buy shares of TriSalus Life Sciences? Shares of TLSI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of TriSalus Life Sciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that TriSalus Life Sciences investors own include AutoZone (AZO), Intel (INTC), Meta Platforms (META), Merck & Co., Inc. (MRK), TJX Companies (TJX), Abacus Health Products (ABAHF) and Airbnb (ABNB). Company Calendar Last Earnings3/05/2026Today5/29/2026Next Earnings (Estimated)8/11/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (2m+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 TLSI's financial health is in the Red zone, according to TradeSmith. TLSI has been in this zone for over 2 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED PRODUCTS Sub-IndustryMedical Equipment Current SymbolNASDAQ:TLSI Previous SymbolNASDAQ:TLSI CIK1826667 Webtrisaluslifesci.com Phone888-321-5212FaxN/AEmployees106Year Founded2009Price Target and Rating Average Price Target for TriSalus Life Sciences$7.50 High Price Target$8.00 Low Price Target$7.00 Potential Upside/Downside+121.6%Consensus RatingHold Rating Score (0-4)2.25 Research Coverage4 Analysts Profitability EPS (Trailing Twelve Months)($1.41) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$39.23 million Net Margins-60.85% Pretax Margin-60.84% Return on EquityN/A Return on Assets-69.91% Debt Debt-to-Equity Ratio2.58 Current Ratio5.78 Quick Ratio5.46 Sales & Book Value Annual Sales$45.15 million Price / Sales4.60 Cash FlowN/A Price / Cash FlowN/A Book Value$0.21 per share Price / Book16.12Miscellaneous Outstanding Shares61,420,000Free Float51,406,000Market Cap$207.91 million OptionableNot Optionable Beta0.56 Social Links Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report This page (NASDAQ:TLSI) was last updated on 5/29/2026 by MarketBeat.com Staff. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredSpaceX just filed. The clock is ticking.Reuters reports Elon Musk filed secretly. Barron's says it's being finalized behind closed doors. CNBC just re...The Oxford Club | SponsoredSpaceX will mint billionaires. You won't be one of them.By the time a company goes public, 95% of profits have already been made. Insiders bought SpaceX at $20 billio...Behind the Markets | SponsoredSpaceX IPO hides a much bigger storyThe SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. ...Weiss Ratings | SponsoredHey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...Banyan Hill Publishing | SponsoredTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding TriSalus Life Sciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share TriSalus Life Sciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free TLSI Stock Alerts